Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma
NCT03829969Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jan 2019
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Toripalimab + Chemotherapy with Placebo + Chemotherapy (2 arms). Primary endpoints: Progression-Free Survival up to 2 years and Overall Survival up to 2 years. Started Jan 2019; status: completed.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03829969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829969.